Management of Diuretics and Electrolyte Disturbances in Cirrhotic Patients with Ascites

Immediate Discontinuation of Harmful Medications

Stop spironolactone when serum potassium exceeds 5.0 mmol/L, because aldosterone antagonists increase the risk of life‑threatening hyper‑kalemia in cirrhosis; this is a Class I guideline recommendation. 1
Discontinue lisinopril (ACE inhibitor) in patients with cirrhotic ascites, as ACE inhibitors aggravate hypotension, worsen renal function, and potentiate hyper‑kalemia. 6

Continue furosemide as monotherapy at 20 mg daily when spironolactone is stopped for hyper‑kalemia; loop‑diuretic monotherapy is endorsed by guidelines for this scenario. 2

Reduce or temporarily stop all diuretics when serum sodium falls below 125 mmol/L; the patient’s Na = 124 mmol/L meets this threshold. 2
Implement fluid restriction to 1–1.5 L per day for severe hyponatremia in cirrhosis. 6
Maintain dietary sodium restriction to approximately 5 g per day (≈ 88 mmol sodium). 1

Diuretic‑induced renal impairment is defined as an increase in serum creatinine >0.3 mg/dL within 48 h or a 1.5‑fold rise within 1 week; the patient’s creatinine of 1.8 mg/dL and BUN 41 mg/dL indicate diuretic contribution. 1

Check serum potassium, sodium, creatinine, and BUN within 24–48 hours of medication adjustment. 10
Perform an ECG within 24–48 hours to detect hyper‑kalemic cardiac changes. 2
Assess volume status (weight, peripheral edema, ascites) within 24–48 hours. 5
Repeat electrolyte panel within 1 week to confirm correction. 10

Restart furosemide alone at 20–40 mg daily once potassium is <5.0 mmol/L and sodium is >125–130 mmol/L, provided ascites persists. 1
Loop diuretics are preferred over spironolactone when hyper‑kalemia is a concern, reflecting a higher safety profile. 11
Do not restart spironolactone until potassium has normalized and remains stable; if needed later, use the lowest effective dose (≈ 25 mg) and re‑check potassium within 1 week. 2
Never restart lisinopril in cirrhotic ascites, as ACE inhibitors have no therapeutic role and cause harm. 6

Avoid the combination of spironolactone and an ACE inhibitor; this pairing precipitates severe electrolyte disturbances and renal dysfunction. 1
Do not continue any diuretics while acute kidney injury is present (elevated creatinine ≥ 1.8 mg/dL) until renal function stabilizes. 1

Recognize that hyper‑kalemia can cause bradycardia; correcting potassium should improve heart rate.
Beta‑blocker therapy, when used for portal hypertension, may exacerbate bradycardia in the setting of electrolyte abnormalities. 8